[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.106.142. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
This Month in Archives of Dermatology
December 15, 2008

This Month in Archives of Dermatology

Author Affiliations
 

ROBIN L.TRAVERSMD

Arch Dermatol. 2008;144(12):1554. doi:10.1001/archdermatol.2008.525

Infantile hemangiomas (IHs) are the most common tumor of infancy. They typically follow a well-described natural history of rapid growth during infancy followed by gradual involution. Although most IHs reach their maximum size by patient age 10 months, a small subset can continue to grow beyond this time. In this retrospective case series, Brandling-Bennett et al demonstrate that prolonged IH growth was observed primarily in the minority of tumors that demonstrated a deep component and segmental morphologic characteristics. Early recognition of these characteristics may alert parents and providers to consider more aggressive therapy.

See page 1632

Dapsone is a sulfone with both antiinflammatory and antimicrobial properties. Systemic use may be associated with hematologic adverse effects such as dose-dependent hemolysis. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more sensitive to developing hemolytic anemia after exposure to hemolytic stressors such as dapsone. A topical formulation of dapsone was recently developed and found effective in the treatment of acne vulgaris. In this double-blinded, randomized, vehicle-controlled study, Piette et al found no clinical or laboratory evidence of drug-induced hemolytic anemia in G6PD-deficient subjects after 12 weeks of therapy with topical dapsone gel, supporting the excellent safety profile of this acne medication.

×